Dynakin is a young company (2004) with very good expectation of growth in the Biosciences. This evolving sector will constitute a revolution in the XXI century because of its foreseeable impact on quality of life. Dynakin provides GLP laboratory and translational medicine modeling & simulation services for the long and costly process of drug development all under the same roof while meeting international quality standards.

As a CRO, Dynakin and its partners are uniquely poised for initiating collaboration with industry clients immediately after the first animal blood samples, much earlier than the typical late Phase I or IIa. Our services smoothly cover all phases and needs of drug development from preclinical to clinical GLP laboratory and also strategic decision making through Model Based Drug Development (MBDD) methods applied by our Consulting group and on to report writing for registration and post-marketing. Dynakin provides adapted and integral solutions with increased flexibility towards the needs of our customers while offering competitive pricing.

The Life Sciences related industry is characterized by its close relationship with research and innovation. Dynakin's R&D activities (30% of annual busget) are strongly directed towards Personalized Medicine through the development of methods and products for Prediction of the Optimal Dose for drugs with narrow therapeutic range mostly in oncology and immunosuppression and in pediatrics.